Sysmex

Skip Navigation

SearchMenu

Management Policies

Message from the Chairman and CEO

Overseas sales continued to grow, and net sales and profits were up year on year.

代表取締役会長兼社長 家次 恒

May 2019

家次 恒

Sales rose in all overseas regions on both a yen and a local currency basis.

 

Profit attributable to owners of the parent increased due to a lower tax rate, despite the impact of an exchange loss.

 

  

During the fiscal year ended March 31, 2019, overseas sales expanded in all regions on both a yen and local currency basis. Although the Company experienced an exchange loss, profit attributable to owners of the parent rose due to a lower tax rate and other factors. Net sales were up 4.1% year on year, operating profit was up 3.7%, and profit attributable to owners of the parent was up 5.1%. At the exchange rates prevailing one year earlier, net sales would have been up 5.5% year on year, and operating profit up 3.4%.

  

 

Due to the dissolution of a joint venture with bioMérieux, sales in Japan were down, despite increasing in certain fields, particularly urinalysis, immunochemistry and life science. Overseas, sales were robust, centering on the hematology1 field, with sales increasing in all overseas regions. As a result, the Sysmex Group’s overseas sales ratio amounted to 85.0%.

 

 

At the start of the year, we had forecast dividends of ¥68 per share (an interim dividend of ¥34 and a year-end dividend of ¥34). Actual dividend payments were ¥2 higher, at ¥70 per share (an interim dividend of ¥34 and a year-end dividend of ¥36). This amounted to the 17th consecutive year of dividend increases and a consolidated dividend payout ratio of 35.4%. We plan to continue paying stable dividends going forward.

    

 

For the fiscal year ending March 31, 2020, we forecast consolidated net sales of ¥320.0 billion, operating profit of ¥64.0 billion and profit attributable to owners of the parent of ¥42.0 billion.2 We also expect to pay dividends for the year amounting to ¥72 per share.

 

 

1 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.

2 The forecasts were calculated on the basis of assumed exchange rates of USD1.00 = JPY110.0, EUR1.00 = JPY125.0 and CNY1 = JPY16.5.


Back to "Management Policies"